The atypical dopamine transporter inhibitor CE-158 enhances dopamine neurotransmission in the prefrontal cortex of male rats: a behavioral, electrophysiological and microdialysis study

CONCLUSIONS: Altogether, these findings confirm CE-158 as a promising pro-cognitive agent and contribute to assessing its preclinical safety profile in a chronic administration regimen for further translational testing.

via https://pubmed.ncbi.nlm.nih.gov/37725477/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20231002010908&v=2.17.9.post6+86293ac